307 related articles for article (PubMed ID: 22551036)
21. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial.
O'Malley SS; Robin RW; Levenson AL; GreyWolf I; Chance LE; Hodgkinson CA; Romano D; Robinson J; Meandzija B; Stillner V; Wu R; Goldman D
Alcohol Clin Exp Res; 2008 Jul; 32(7):1271-83. PubMed ID: 18482155
[TBL] [Abstract][Full Text] [Related]
22. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
[TBL] [Abstract][Full Text] [Related]
23. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.
Lin Y; Kranzler HR; Farrer LA; Xu H; Henderson DC; Zhang H
Pharmacogenomics J; 2020 Oct; 20(5):672-680. PubMed ID: 32029903
[TBL] [Abstract][Full Text] [Related]
24. Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial.
Schacht JP; Voronin KE; Randall PK; Anton RF
Neuropsychopharmacology; 2018 May; 43(6):1247-1256. PubMed ID: 29362512
[TBL] [Abstract][Full Text] [Related]
25. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
Kim SG; Kim CM; Choi SW; Jae YM; Lee HG; Son BK; Kim JG; Choi YS; Kim HO; Kim SY; Oslin DW
Psychopharmacology (Berl); 2009 Jan; 201(4):611-8. PubMed ID: 18795264
[TBL] [Abstract][Full Text] [Related]
26. Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.
Morley KC; Kranzler HR; Luquin N; Jamshidi N; Adams C; Montebello M; Tremonti C; Dali G; Logge W; Baillie A; Teesson M; Trent R; Haber PS
Am J Psychiatry; 2024 May; 181(5):403-411. PubMed ID: 38706338
[TBL] [Abstract][Full Text] [Related]
27. Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence.
Anton RF; Latham PK; Voronin KE; Randall PK; Book SW; Hoffman M; Schacht JP
Alcohol Clin Exp Res; 2018 Apr; 42(4):751-760. PubMed ID: 29431852
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans.
Arias AJ; Gelernter J; Gueorguieva R; Ralevski E; Petrakis IL
Am J Addict; 2014; 23(3):288-93. PubMed ID: 24724887
[TBL] [Abstract][Full Text] [Related]
29. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
[TBL] [Abstract][Full Text] [Related]
30. Independent and Interactive Effects of OPRM1 and DAT1 Polymorphisms on Alcohol Consumption and Subjective Responses in Social Drinkers.
Weerts EM; Wand GS; Maher B; Xu X; Stephens MA; Yang X; McCaul ME
Alcohol Clin Exp Res; 2017 Jun; 41(6):1093-1104. PubMed ID: 28376280
[TBL] [Abstract][Full Text] [Related]
31. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.
Oslin DW; Berrettini W; Kranzler HR; Pettinati H; Gelernter J; Volpicelli JR; O'Brien CP
Neuropsychopharmacology; 2003 Aug; 28(8):1546-52. PubMed ID: 12813472
[TBL] [Abstract][Full Text] [Related]
32. OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients.
Foulds JA; Ton K; Kennedy MA; Adamson SJ; Mulder RT; Sellman JD
Pharmacogenet Genomics; 2015 May; 25(5):270-3. PubMed ID: 25715171
[TBL] [Abstract][Full Text] [Related]
33. OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.
Hendershot CS; Dermody SS; Wardell JD; Zaso MJ; Kennedy JL; Stoner SA
Alcohol Clin Exp Res; 2020 Apr; 44(4):983-991. PubMed ID: 32020635
[TBL] [Abstract][Full Text] [Related]
34. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
Coller JK; Cahill S; Edmonds C; Farquharson AL; Longo M; Minniti R; Sullivan T; Somogyi AA; White JM
Pharmacogenet Genomics; 2011 Dec; 21(12):902-5. PubMed ID: 21946895
[TBL] [Abstract][Full Text] [Related]
35. Influence of the A118G Polymorphism of the OPRM1 Gene and Exon 3 VNTR Polymorphism of the DRD4 Gene on Cigarette Craving After Alcohol Administration.
Lechner WV; Knopik VS; McGeary JE; Spillane NS; Tidey JW; McKee SA; Metrik J; Leventhal AM; Rohsenow DJ; Kahler CW
Nicotine Tob Res; 2016 May; 18(5):632-6. PubMed ID: 26092968
[TBL] [Abstract][Full Text] [Related]
36. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control.
Voronin K; Randall P; Myrick H; Anton R
Alcohol Clin Exp Res; 2008 Nov; 32(11):1954-61. PubMed ID: 18782344
[TBL] [Abstract][Full Text] [Related]
37. Medication-enhanced behavior therapy for alcohol use disorder: Naltrexone, Alcoholics Anonymous Facilitation, and OPRM1 genetic variation.
Stewart SH; Walitzer KS; Blanco J; Swiatek D; Paine Hughes L; Quiñones-Lombraña A; Shyhalla K
J Subst Abuse Treat; 2019 Sep; 104():7-14. PubMed ID: 31370987
[TBL] [Abstract][Full Text] [Related]
38. The μ-opioid receptor and treatment response to naltrexone.
Thorsell A
Alcohol Alcohol; 2013; 48(4):402-8. PubMed ID: 23543091
[TBL] [Abstract][Full Text] [Related]
39. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking.
Anton RF; Drobes DJ; Voronin K; Durazo-Avizu R; Moak D
Psychopharmacology (Berl); 2004 Apr; 173(1-2):32-40. PubMed ID: 14722705
[TBL] [Abstract][Full Text] [Related]
40. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene.
Drobes DJ; Anton RF; Thomas SE; Voronin K
Neuropsychopharmacology; 2003 Apr; 28(4):755-64. PubMed ID: 12655322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
